493 related articles for article (PubMed ID: 25851829)
21. Second primaries after major salivary gland cancer.
Megwalu UC; Shin EJ
Otolaryngol Head Neck Surg; 2011 Aug; 145(2):254-8. PubMed ID: 21493280
[TBL] [Abstract][Full Text] [Related]
22. Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.
Lang BH; Lo CY; Wong IO; Cowling BJ
Surgery; 2010 Dec; 148(6):1191-6; discussion 1196-7. PubMed ID: 21134551
[TBL] [Abstract][Full Text] [Related]
23. Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel.
Izkhakov E; Barchana M; Liphshitz I; Silverman BG; Stern N; Keinan-Boker L
Thyroid; 2017 Jun; 27(6):793-801. PubMed ID: 28338430
[TBL] [Abstract][Full Text] [Related]
24. Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015.
Park KW; Wu JX; Du L; Leung AM; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):1095-1101. PubMed ID: 29267880
[TBL] [Abstract][Full Text] [Related]
25. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas.
Kim C; Bi X; Pan D; Chen Y; Carling T; Ma S; Udelsman R; Zhang Y
Thyroid; 2013 May; 23(5):575-82. PubMed ID: 23237308
[TBL] [Abstract][Full Text] [Related]
26. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
27. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
28. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
[TBL] [Abstract][Full Text] [Related]
29. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
30. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
[TBL] [Abstract][Full Text] [Related]
31. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
[TBL] [Abstract][Full Text] [Related]
32. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
[TBL] [Abstract][Full Text] [Related]
33. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
34. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
35. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
Hisada M; Chen BE; Jaffe ES; Travis LB
J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
[TBL] [Abstract][Full Text] [Related]
36. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer.
Jain KS; Sikora AG; Baxi SS; Morris LG
Cancer; 2013 May; 119(10):1832-7. PubMed ID: 23423883
[TBL] [Abstract][Full Text] [Related]
37. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
38. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
Gandhi S; Abhyankar A; Basu S
Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
Sacks W; Fung CH; Chang JT; Waxman A; Braunstein GD
Thyroid; 2010 Nov; 20(11):1235-45. PubMed ID: 21062195
[TBL] [Abstract][Full Text] [Related]
40. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]